Skin Cancer - How To Reduce Your Risk | Dr. Thomas Dobbs - NHS (Melanoma & Skin Cancer Awareness Month)

What Should I Eat? Nutrition Principles Everyone Should Know | Dr. Jaime Schehr

Poor diet is one of the biggest drivers of chronic disease worldwide.  In this episode of The Health Curve, we explore one of the most basic but most confusing questions in health: what should people actually eat? Host Dr. Jason Arora is joined by Dr. Jaime Schehr - integrative medicine physician, naturopathic doctor, registered dietitian, and Peloton's official Nutritionist @OnePeloton 🚴 - to cut through the noise on food, wellness, and the diets people are constantly told to follow. Together, they break down the nutrition principles that matter most: why whole, recognizable foods matter, why most people need more fiber, how to think about protein, carbohydrates, fats, dairy, and micronutrients, and why so much of the confusion around food comes from misinformation, overprocessing, and convenience-driven eating. The conversation also gets practical. What does a healthy plate actually look like? How should people think about smoothies, sugar, seed oils, hidden fats, and ultra-processed foods? And how can someone eat well even on a tight budget? At its core, this episode is about simplifying nutrition. Not fad diets. Not food fear. Just the core principles that help most people eat better, feel better, and reduce their long-term risk of disease. Follow The Health Curve @thehealthcurve for evidence-based conversations that make it easier to navigate health with clarity. Chapters: 00:00 Intro 00:23 Dr. Jaime Schehr's background 03:13 Wellness trends and what's changed 07:53 Where nutrition fits in health today 11:22 Why nutrition feels so confusing 13:03 What a healthy diet actually looks like 17:01 What changed in the food pyramid 18:31 Do people eat enough protein? 21:43 How to eat healthy on a budget 24:52 Seed oils and ultra-processed foods 30:53 Why fiber matters so much 35:03 Carbohydrates explained 37:39 Smoothies, fruit, and sugar 42:21 Dairy explained 44:21 What micronutrients are 46:27 Where nutrition needs to go next 47:44 Closing thoughts

Skin Cancer - How To Reduce Your Risk | Dr. Thomas Dobbs - NHS (Melanoma & Skin Cancer Awareness Month)

Skin cancer is the most common cancer in the world. In this episode of The Health Curve, we explore how to actually reduce your risk - what matters, what doesn’t, and what most people get wrong. Host Dr. Jason Arora is joined by Dr. Thomas Dobbs, NHS plastic surgeon and skin cancer specialist, to break down the basics: what skin cancer is, why it’s so common, and how it develops. Together, we unpack the key risk factors (sun exposure, burns, tanning beds, skin type, age, and more), the main types of skin cancer, and what to look for on your own skin. We also get practical about prevention. When should you use sunscreen? What does SPF actually mean? Do you need it on cloudy days? And how should you apply it properly? Finally, we cut through the noise on some of the biggest myths online - does sunscreen actually cause cancer? Does it block vitamin D? Are certain ingredients unsafe? - and bring it back to what the evidence actually says. If you care about your long-term health, this is one of the simplest areas where small habits can make a big difference. Follow The Health Curve  @thehealthcurve [https://studio.youtube.com/channel/UCQqXmV-9UHvdd-BRnQkw1VQ]for evidence-based conversations that help you navigate your health with clarity.

How Close Are We To Slowing Aging? | Dr. Eric Verdin, President and CEO of the Buck Institute for Research on Aging

What if aging itself becomes something we can measure, slow, and eventually treat? In this episode of The Health Curve Podcast, host Dr. Jason Arora sits down with Dr. Eric Verdin, President and CEO of the Buck Institute for Research on Aging, to explore one of the biggest questions in science today: how close are we really to slowing human aging? Dr. Verdin has spent decades at the forefront of aging biology, from early discoveries in epigenetics to leading one of the world’s premier longevity research institutes. In this conversation, he explains what fundamentally changed the field of aging research, why scientists are now more optimistic than ever, and what still stands in the way of translating these breakthroughs into real-world impact. They discuss how aging shifted from being seen as a passive, inevitable process to something that can be actively influenced at the molecular level. They unpack the scientific bottlenecks that have slowed progress in humans, including long timelines, safety requirements, and the lack of a clear regulatory pathway for targeting aging itself. The conversation also dives into emerging tools like epigenetic clocks and biomarkers of aging, which may allow us to measure biological age and track interventions in real time. They explore how AI and “digital twins” could accelerate research, and why funding, regulation, and existing healthcare incentives remain major constraints. Beyond the science, this episode asks a deeper question: if we do succeed in extending human healthspan and lifespan, are we ready for the consequences? From inequality and access to environmental pressures and system design, Dr. Verdin shares a grounded, realistic perspective on what the future might look like. They also discuss what actually matters today. From exercise, sleep, and social connection to the realities of supplements and longevity clinics, this episode separates what is actionable now from what remains experimental or overhyped. If you’re trying to understand where longevity science really stands, and what it means for your life, your health, and society, this is a conversation you don’t want to miss. Follow The Health Curve on YouTube for evidence-based conversations that cut through hype and help you navigate your health with clarity. Chapters: 00:00 Intro  00:04 Welcome and Dr. Eric Verdin’s background  02:12 The discoveries that changed aging research  05:55 Why translating aging science to humans is so hard  07:31 AI, simulation, and digital twins in aging research  10:19 Aging as a scientific and cultural inflection point  12:26 How close are we to slowing aging in humans?  15:21 What we can do now vs future anti-aging drugs  15:44 Funding, regulation, and system barriers  19:58 Biomarkers, epigenetic clocks, and biological age  23:21 Subscribe and share  24:06 Dr. Verdin’s personal longevity habits  27:34 Supplements, hype, and regulation gaps  28:11 Zip code health and social determinants  32:30 Can drugs replace lifestyle?  35:57 The rise of longevity medicine  39:46 What’s real vs fluff in longevity today  41:05 Are we ready for longer lives?  44:13 AI, aging, and the future  44:50 Closing thoughts

Fatty Liver: The Silent Disease at the Heart of the Metabolic Crisis | Mazen Noureddin MD, Houston Liver Institute

🧠 Most people have heard of heart disease, diabetes, and obesity, but far fewer have been told about fatty liver, even though it now affects nearly 1 in 3 adults and sits at the center of all three. In this episode of The Health Curve, Dr. Jason Arora is joined by Dr. Mazen Noureddin MD (Transplant Hepatologist, Professor of Medicine, and Founding Director of the Houston Liver Institute), one of the world’s leading experts in liver and metabolic disease, to unpack why fatty liver disease is not a niche diagnosis, but a defining feature of modern metabolic illness. They explore what fatty liver actually is, why it often progresses silently for years, and how excess fat in the liver fuels inflammation, insulin resistance, cardiovascular disease, kidney disease, and shortened healthspan ⚠️. The conversation reframes fatty liver not as an isolated organ problem, but as a metabolic warning sign that the body’s systems are under strain. Dr. Noureddin explains how fatty liver progresses from early fat accumulation to inflammation, scarring, and cirrhosis, often without obvious symptoms, and why so many people are still diagnosed too late. They also discuss who is most at risk (including people with type 2 diabetes, metabolic risk factors, and even those who are not overweight), how fatty liver is detected, and what simple tests can identify people who need urgent follow-up 🧪. Importantly, this episode also brings hope. When caught early, fatty liver disease can be reversed. Dr. Arora and Dr. Noureddin walk through what actually works, from lifestyle interventions to newer FDA-approved therapies, while debunking common myths, internet misinformation, and false assumptions about alcohol, weight, and supplements 🌱💊. Chapter Markers: 00:00 – Why fatty liver matters more than people realize 00:40 – What the liver actually does in metabolic health 01:45 – Why fatty liver sits at the center of cardiometabolic disease 02:10 – How excess fat builds up in the liver 03:30 – From fatty liver to inflammation, scarring, and cirrhosis 04:25 – What happens to the body as liver damage progresses 05:50 – Why fatty liver often has no early symptoms 06:15 – MAFLD, MASH, and the new terminology explained 07:35 – How fatty liver connects to diabetes, heart disease, and kidney disease 08:15 – Why these diseases “travel together” 09:15 – How people usually discover they have fatty liver 09:40 – Who should be screened — and why many cases are still missed 10:30 – Simple blood tests and the FIB-4 score explained 11:25 – Why early detection changes everything 11:35 – Can fatty liver be reversed? 12:05 – Lifestyle changes that actually work 13:10 – Diet patterns with the strongest evidence 14:00 – Medications for fatty liver: what’s now FDA-approved 15:40 – Common myths about fatty liver debunked 16:50 – Supplements, alcohol, and misinformation 17:15 – Key takeaways and closing reflections

Obesity Isn’t a Willpower Problem - It’s a Chronic Disease | Marc-Andre Cornier MD, The Obesity Society & MUSC

🧠🍽️ Obesity and being overweight are often talked about like personal failures, but the science tells a very different story. In this episode of The Health Curve Podcast, Dr. Jason Arora and Dr. Marc-André Cornier (Past President of The Obesity Society, Professor of Medicine, and Director of the Division of Endocrinology at MUSC) explore obesity as a chronic, progressive disease shaped by biology 🧬 and an “obesogenic” environment. Together, they unpack why obesity rates have risen so dramatically worldwide, how risk and complications vary across populations 🫀, and why low socioeconomic environments and “food deserts” can quietly stack the odds against health 🏙️. They also discuss why childhood obesity is so concerning 🧒📱, and what it means for long-term health systems, productivity, and society. They also explore what evidence-based obesity care actually looks like today, walking through the full toolbox - from lifestyle foundations 🥗🏃 and medications (including GLP-1–based therapies) 💉 to bariatric surgery 🏥 , plus the hard truth that long-term disease often requires long-term treatment ⏳. They also tackle common fears and criticisms: side effects, cost and access 💸, direct-to-consumer “quick fixes” 🧪, and the tension between prevention and treatment. If you’ve ever wondered why weight loss can feel like your body is fighting you - and what a smarter, more compassionate, science-based approach looks like - this episode is for you 💙. Chapters" 00:00 – Introduction and guest background 01:10 – Why obesity is rising: genes × “obesogenic” environments 03:15 – Why obesity risk differs across populations and regions 04:20 – Visceral vs subcutaneous fat: metabolic vs mechanical health impacts 05:50 – The environmental drivers: food deserts, safety, inactivity, marketing 06:55 – Why childhood obesity is accelerating 08:20 – The societal and economic spillovers of obesity 10:50 – Why obesity meets the definition of a chronic disease 13:05 – Patient archetypes: cosmetic vs health vs “not on the radar” 14:30 – The obesity treatment toolbox: lifestyle, meds, surgery, teams 20:00 – Who should get what? BMI limits, waist measures, risk staging 23:35 – Expected weight-loss ranges: lifestyle vs GLP-1s vs surgery 26:10 – Long-term challenges: cost, coverage, adherence, access 29:15 – Side effects and safe prescribing: why supervision matters 31:35 – Direct-to-consumer risks, compounded meds, and regulation 33:45 – Prevention vs treatment: why it’s not either/or 36:30 – “Big food vs big pharma” concerns and stigma 39:50 – The future of obesity care: primary care, centers, virtual models 43:20 – What’s next in meds: multi-agonists, longer-acting options, muscle preservation